Activation of the cGAS-STING pathway has been proved to have significant potential in promoting anti-tumor immunity, especially in enhancing tumor efficacy against immune checkpoint inhibitors such as PD-1/PD-L1 antibodies (56–59). Here, STING1 is linked to neoplasm.